Rezafungin chloride

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 412468

CAS#: Rezafungin chloride

Description: Rezafungin (formerly CD101) is a new β-glucan synthase inhibitor that is chemically related with anidulafungin. Rezafungin is a novel echinocandin (form of antifungal) with enhanced stability and pharmacokinetics that achieves high plasma drug exposure and allows for once weekly dose administration. Rezafungin has been shown comparable to other echinocandins, with activity against Candida spp. and Aspergillus spp. including subsets of echinocandin-resistant Candida auris and azole-resistant Aspergillus isolates.

Chemical Structure

Rezafungin chloride
CAS# Rezafungin chloride

Theoretical Analysis

MedKoo Cat#: 412468
Name: Rezafungin chloride
CAS#: Rezafungin chloride
Chemical Formula: C63H85ClN8O17
Exact Mass: 1225.6027
Molecular Weight: 1261.862
Elemental Analysis: C, 59.97; H, 6.79; Cl, 2.81; N, 8.88; O, 21.55

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Related CAS #: 1631754-41-0 (acetate)   1396640-59-7 (cation)   1396640-60-0 (TFA)   Rezafungin chloride    

Synonym: Rezafungin; CD 101; CD-101; CD101; Rezafungin Chloride;

IUPAC/Chemical Name: 2-(((2R,6S,9S,11R,12R,14aS,15S,16S,20S,25aS)-23-((1S,2S)-1,2-dihydroxy-2-(4-hydroxyphenyl)ethyl)-2,11,15-trihydroxy-6,20-bis((R)-1-hydroxyethyl)-16-methyl-5,8,14,19,22,25-hexaoxo-9-(4''-(pentyloxy)-[1,1':4',1''-terphenyl]-4-carboxamido)tetracosahydro-1H-dipyrrolo[2,1-c:2',1'-l][1,4,7,10,13,16]hexaazacyclohenicosin-12-yl)oxy)-N,N,N-trimethylethan-1-aminium chloride


InChi Code: InChI=1S/C63H84N8O17.ClH/c1-8-9-10-28-87-45-25-21-40(22-26-45)38-13-11-37(12-14-38)39-15-17-42(18-16-39)56(80)64-46-31-48(76)61(88-29-27-71(5,6)7)68-60(84)52-53(77)34(2)32-70(52)63(86)50(36(4)73)66-59(83)51(55(79)54(78)41-19-23-43(74)24-20-41)67-58(82)47-30-44(75)33-69(47)62(85)49(35(3)72)65-57(46)81;/h11-26,34-36,44,46-55,61,72-73,75-79H,8-10,27-33H2,1-7H3,(H5-,64,65,66,67,68,74,80,81,82,83,84);1H/t34-,35+,36+,44+,46-,47-,48+,49-,50-,51-,52-,53-,54-,55-,61+;/m0./s1

SMILES Code: O=C1N2[C@]([C@H]([C@H](C2)C)O)([H])C(N[C@@H]([C@@H](C[C@@H](C(N[C@@](C(N3[C@](C[C@H](C3)O)([H])C(N[C@@](C(N[C@@]1([H])[C@H](O)C)=O)([H])[C@H](O)[C@H](C4=CC=C(C=C4)O)O)=O)=O)([H])[C@H](O)C)=O)NC(C5=CC=C(C6=CC=C(C7=CC=C(C=C7)OCCCCC)C=C6)C=C5)=O)O)OCC[N+](C)(C)C)=O.[Cl-]

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >3 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Preparing Stock Solutions

The following data is based on the product molecular weight 1261.862 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.


Dilution Calculator

Calculate the dilution required to prepare a stock solution.

1: Alsowaida YS, Alamer A, Thabit AK, Almulhim AS, Aleissa MM, Kalbasi A, Eljaaly K, Almangour TA, Erstad BL. Echinocandin exposures in obese patients: A scoping review and clinical perspectives. Am J Health Syst Pharm. 2023 Jan 21:zxad021. doi: 10.1093/ajhp/zxad021. Epub ahead of print. PMID: 36680786.

2: Sharma N, Wani SN, Behl T, Singh S, Zahoor I, Sehgal A, Bhatia S, Al-Harrasi A, Aleya L, Bungau S. Focusing COVID-19-associated mucormycosis: a major threat to immunocompromised COVID-19. Environ Sci Pollut Res Int. 2023 Jan;30(4):9164-9183. doi: 10.1007/s11356-022-24032-2. Epub 2022 Dec 1. PMID: 36454526; PMCID: PMC9713750.

3: Thompson GR 3rd, Soriano A, Cornely OA, Kullberg BJ, Kollef M, Vazquez J, Honore PM, Bassetti M, Pullman J, Chayakulkeeree M, Poromanski I, Dignani C, Das AF, Sandison T, Pappas PG; ReSTORE trial investigators. Rezafungin versus caspofungin for treatment of candidaemia and invasive candidiasis (ReSTORE): a multicentre, double-blind, double-dummy, randomised phase 3 trial. Lancet. 2023 Jan 7;401(10370):49-59. doi: 10.1016/S0140-6736(22)02324-8. Epub 2022 Nov 25. PMID: 36442484.

4: Guinea J. Rezafungin and invasive candida infections: a new game changing antifungal? Lancet. 2023 Jan 7;401(10370):3-5. doi: 10.1016/S0140-6736(22)02371-6. Epub 2022 Nov 25. PMID: 36442483.

5: Treviño-Rangel RJ, González GM, Montoya AM, Rojas OC, Elizondo-Zertuche M, Álvarez-Villalobos NA. Recent Antifungal Pipeline Developments against Candida auris: A Systematic Review. J Fungi (Basel). 2022 Oct 28;8(11):1144. doi: 10.3390/jof8111144. PMID: 36354911; PMCID: PMC9695453.

6: Stafylidis C, Diamantopoulos P, Athanasoula E, Solomou E, Anastasopoulou A. Acute Lymphoblastic Leukemia and Invasive Mold Infections: A Challenging Field. J Fungi (Basel). 2022 Oct 26;8(11):1127. doi: 10.3390/jof8111127. PMID: 36354894; PMCID: PMC9696423.

7: Arendrup MC, Arikan-Akdagli S, Castanheira M, Guinea J, Locke JB, Meletiadis J, Zaragoza O. Multicentre validation of a modified EUCAST MIC testing method and development of associated epidemiologic cut-off (ECOFF) values for rezafungin. J Antimicrob Chemother. 2022 Dec 23;78(1):185-195. doi: 10.1093/jac/dkac373. PMID: 36329639.

8: Li H, Cao YB, Yan TH, Jiang YY, Yang F. Aneuploidy underlies paradoxical growth of rezafungin and enables cross-tolerance to echinocandins in Candida albicans. J Infect. 2022 Dec;85(6):702-769. doi: 10.1016/j.jinf.2022.09.028. Epub 2022 Oct 1. PMID: 36191677.

9: Siopi M, Papadopoulos A, Spiliopoulou A, Paliogianni F, Abou-Chakra N, Arendrup MC, Damoulari C, Tsioulos G, Giannitsioti E, Frantzeskaki F, Tsangaris I, Pournaras S, Meletiadis J. Pan-Echinocandin Resistant C. parapsilosis Harboring an F652S Fks1 Alteration in a Patient with Prolonged Echinocandin Therapy. J Fungi (Basel). 2022 Sep 1;8(9):931. doi: 10.3390/jof8090931. PMID: 36135656; PMCID: PMC9502558.

10: Wiederhold NP. Pharmacodynamics, Mechanisms of Action and Resistance, and Spectrum of Activity of New Antifungal Agents. J Fungi (Basel). 2022 Aug 16;8(8):857. doi: 10.3390/jof8080857. PMID: 36012845; PMCID: PMC9410397.

11: Jo J, Tran TT, Beyda ND, Simmons D, Hendrickson JA, Almutairi MS, Alnezary FS, Gonzales-Luna AJ, Septimus EJ, Garey KW. Development of the invasive candidiasis discharge [I Can discharge] model: a mixed methods analysis. Eur J Clin Microbiol Infect Dis. 2022 Oct;41(10):1207-1213. doi: 10.1007/s10096-022-04473-w. Epub 2022 Aug 25. PMID: 36002777; PMCID: PMC9489576.

12: Logan A, Wolfe A, Williamson JC. Antifungal Resistance and the Role of New Therapeutic Agents. Curr Infect Dis Rep. 2022;24(9):105-116. doi: 10.1007/s11908-022-00782-5. Epub 2022 Jul 5. PMID: 35812838; PMCID: PMC9255453.

13: Carvalhaes CG, Rhomberg PR, Pfaller MA, Locke JB, Castanheira M. Evaluation of the Post-Antifungal Effect of Rezafungin and Micafungin against Candida albicans, Candida parapsilosis and Candida glabrata. Mycoses. 2022 Nov;65(11):1040-1044. doi: 10.1111/myc.13490. Epub 2022 Jul 18. PMID: 35778886.

14: Pechacek J, Yakubu I, Vissichelli NC, Bruno D, Morales MK. Successful expanded access use of rezafungin, a novel echinocandin, to eradicate refractory invasive candidiasis in a liver transplant recipient. J Antimicrob Chemother. 2022 Aug 25;77(9):2571-2573. doi: 10.1093/jac/dkac206. PMID: 35770840.

15: Domingos EL, Vilhena RO, Santos JMMF, Fachi MM, Böger B, Adam LM, Tonin FS, Pontarolo R. Comparative efficacy and safety of systemic antifungal agents for candidemia: a systematic review with network meta-analysis and multicriteria acceptability analyses. Int J Antimicrob Agents. 2022 Aug;60(2):106614. doi: 10.1016/j.ijantimicag.2022.106614. Epub 2022 Jun 9. PMID: 35691603.

16: Hoenigl M, Sprute R, Arastehfar A, Perfect JR, Lass-Flörl C, Bellmann R, Prattes J, Thompson GR 3rd, Wiederhold NP, Al Obaidi MM, Willinger B, Arendrup MC, Koehler P, Oliverio M, Egger M, Schwartz IS, Cornely OA, Pappas PG, Krause R. Invasive candidiasis: investigational drugs in the clinical development pipeline and mechanisms of action. Expert Opin Investig Drugs. 2022 Aug;31(8):795-812. doi: 10.1080/13543784.2022.2086120. Epub 2022 Jun 15. PMID: 35657026; PMCID: PMC9339492.

17: Adeel A, Qu MD, Siddiqui E, Levitz SM, Ellison RT 3rd. Expanded Access Use of Rezafungin for Salvage Therapy of Invasive Candida glabrata Infection: A Case Report. Open Forum Infect Dis. 2021 Aug 28;8(11):ofab431. doi: 10.1093/ofid/ofab431. PMID: 35559122; PMCID: PMC9088506.

18: Khalfe Y, Rosen T. Future Fungal Fighters in Dermatology: Novel Antifungal Drug Pipeline. J Drugs Dermatol. 2022 May 1;21(5):496-501. doi: 10.36849/JDD.6373. PMID: 35533026.

19: Gu K, Ruff D, Key C, Thompson M, Jiang S, Sandison T, Flanagan S. A phase I randomized, double-blind, single subcutaneous dose escalation study to determine the safety, tolerability, and pharmacokinetics of rezafungin in healthy adult subjects. Clin Transl Sci. 2022 Jul;15(7):1592-1598. doi: 10.1111/cts.13286. Epub 2022 May 4. PMID: 35439347; PMCID: PMC9283735.

20: Jaber QZ, Logviniuk D, Yona A, Fridman M. Echinocandins Localized to the Target-Harboring Cell Surface Are Not Degraded but Those Entering the Vacuole Are. ACS Chem Biol. 2022 May 20;17(5):1155-1163. doi: 10.1021/acschembio.2c00060. Epub 2022 Apr 11. PMID: 35404573; PMCID: PMC9127807.

Additional Information

Rezafungin is considered the first molecule of the new generation of long-acting echinocandins. It has several advantages over the already approved by the Food and Drug Administration (FDA) echinocandins as it has better tissue penetration, better pharmacokinetic/phamacodynamic (PK/PD) pharmacometrics, and a good safety profile. It is much more stable in solution than the older echinocandins, making it more flexible in terms of dosing, storage, and manufacturing. These properties would allow rezafungin to be administered once-weekly (intravenous) and to be potentially administered topically and subcutaneously. In addition, higher dose regimens were tested with no evidence of toxic effect. This will eventually prevent (or reduce) the selection of resistant strains. Rezafungin also has several similarities with older echinocandins as they share the same in vitro behavior (very similar Minimum Inhibitory Concentration required to inhibit the growth of 50% of the isolates (MIC50) and half enzyme maximal inhibitory concentration 50% (IC50)) and spectrum, the same target, and the same mechanisms of resistance. The selection of FKS mutants occurred at similar frequency for rezafungin than for anidulafungin and caspofungin.